Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 15, showing 5 Applications out of 73 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/21/03/01   Recombinant COVID-19 vaccine
    A global multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to evaluate the efficacy, safety, and immunogenicity of recombinant COVID-19 vaccine (Sf9 cells), for the prevention of COVID-19 in adults aged 18 years and older   
Principal Investigator(s)
1. Walter Jaoko Jaoko
Site(s) in Kenya
KAVI-institute of Clinical Research
 
Trial Status (not set!)
Protocol Date 19-02-2021
View

2.

ECCT/21/02/03   VAC078
    A Phase III randomized, controlled, multi-centre trial to evaluate the efficacy of the R21/Matrix-M vaccine in African children against clinical malaria.   
Principal Investigator(s)
1. Mainga Patience Mayeso Hamaluba
2. Jean Bosco Ouedraogo
3. Halidou Tinto
4. Alassane Dicko
5. Ally Olotu
Site(s) in Kenya
KEMRI Wellcome Trust Research Programme
 
Trial Status (not set!)
Protocol Date 05-01-2021
View

3.

ECCT/21/03/02   PB-SAM
    Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children.   
Principal Investigator(s)
1. Robert Bandsma
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast General Hospital (Mombasa county)
3. Mbagathi Hospital (Nairobi City county)
4. Migori County Hospital (Migori county)
 
Trial Status (not set!)
Protocol Date 11-01-2021
View

4.

ECCT/20/12/03   CALINA STUDY
    A multicenter, open-label, single-arm study to evaluate the PK, safety, tolerability and efficacy of a new artemether-lumefantrine (2.5 mg:30 mg) dispersible tablet in the treatment of infants and neonates <5 kg body weight with acute uncomplicated Plasmodium falciparum malaria.   Study number: CCOA566B2307   
Principal Investigator(s)
1. Benhards Ragama Ogutu
Site(s) in Kenya
KEMRI-Centre for Clinical Research (CCR)
 
Trial Status (not set!)
Protocol Date 02-12-2019
View

5.

ECCT/20/10/04   yellow fever vaccine CVIA 079
    A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079.   
Principal Investigator(s)
1. Dr. Deborah Langat
Site(s) in Kenya
KEMRI/KERICHO CLINIC RESEARCH CENTRE
 
Trial Status Recruiting
Protocol Date 16-09-2020
View